Is Vorinostat available in China?

In 2006, the U.S. Food and Drug Administration (FDA) approved subhydroxamic acid, a pan-histone deacetylase inhibitor (HDACi), for patients with cutaneous T-cell lymphoma (CTCL). Similar to other targeted anticancer drugs, Vorinostat was developed based on the hypothesis that it could mediate direct cytotoxic effects on malignant cells. Indeed, vorinostat has been shown to trigger apoptotic death of cancer cells in vivo in syngeneic models of mouse adenocarcinoma and lymphoma and in mice with human acute lymphoblastic leukemia.

Vorinostat, marketed by Merck asZolinza, appears to exert immunomodulatory effects by acting on cancer and immune cells. Vorinostat has immunosuppressive side effects. Vorinostat has been reported to stimulate the function of regulatory T cells to prevent the activation of tumor-specific NK cells and T cells. In the context of its clinical indication CTCL, vorinostat has been found to inhibit the expression of the immunosuppressive cytokine interleukin 1033 and inhibit the cytotoxic effects of NK cells.

The original drug of vorinostat is currently not on the market in China, and therefore cannot be covered by national medical insurance. It is difficult to purchase vorinostat in China. Overseas, there is an American version of the original vorinostat drug. Specifications: 100mg*120 capsules. The price per box may be around 100,000 yuan (the price may fluctuate due to the exchange rate). The price is very expensive. There is currently no generic version of vorinostat on the market. For more drug information and specific prices, please consult a medical consultant.